Two weeks after a stock downturn due to questions about the early closing of Phase IIa enrollment for its first-in-class psoriasis candidate, Vitae Pharmaceuticals Inc. bounced back March 16 with data showing that VTP-43742 offers both efficacy and safety at two doses in patients with moderate to severe plaque psoriasis.
The Phase IIa data were revealed on an after-closing investor call and the computational drug design firm enjoyed a healthy resurgence of its share price, closing March 17 up 65%...